Important drug development questions that model-based meta-analysis answers

Drug development teams know more about their own molecules than ever before. Advances in pharmacometrics have made it possible to characterize pharmacokinetics, understand exposure response relationships, and optimize dose selection with remarkable precision. Those capabilities are fundamental to drug development, but they only answer questions about a single therapy.

As programs advance, the focus naturally shifts beyond the data generated in one clinical trial. Scientific teams, executives, investors, and regulators all want to understand how a therapy compares with the rest of the treatment landscape. Is it truly differentiated? How does it stack up against therapies that have never been evaluated head-to-head? Are the results driven by the treatment itself, or by differences in study design, patient populations, or endpoints?

Answering those questions isn’t easy. Head-to-head trials remain the most reliable way to compare treatments, but they’re expensive, take years to complete, and can’t realistically be conducted against every relevant competitor. At the same time, the volume of published clinical evidence continues to grow, making it increasingly difficult to draw conclusions from individual studies alone. These same evidence gaps show up as practical roadblocks in the clinic; we cover them in five clinical development challenges MBMA helps address.

Model-based meta-analysis (MBMA) was developed to address this challenge by bringing together evidence from multiple studies. By evaluating treatments within the context of an entire therapeutic area, it provides a more complete picture than any single trial can offer.

Below are five of the most important drug development questions that model-based meta-analysis answers, and why those answers can influence development strategy long before a pivotal trial begins.

1. How does our therapy compare with competitors we have never studied?

No development program exists in isolation. By the time a therapy reaches Phase II or Phase III, there may already be dozens of studies evaluating similar mechanisms, competing products, or evolving standards of care. Yet direct comparisons remain surprisingly uncommon because each trial is designed to answer a different scientific question.

Looking only at published response rates rarely tells the whole story. Differences in patient populations, eligibility criteria, background therapies, endpoint definitions, and study duration all influence outcomes, making simple side by side comparisons unreliable.

“One of the biggest challenges sponsors face is understanding where their therapy truly fits within the competitive landscape,” says Zierhut. “The published results only tell part of the story.”

This approach accounts for those differences before making comparisons. Rather than comparing headline efficacy numbers, researchers can evaluate therapies on a more consistent basis, giving sponsors a clearer picture of how their therapy performs relative to existing and emerging competitors.

Those findings often determine whether a program moves forward, how future studies are designed, and where sponsors choose to invest next.

2. What does meaningful differentiation look like?

Every sponsor wants a differentiated product, but determining what meaningful differentiation looks like is often harder than achieving it. Is a five percent improvement enough? Does differentiation depend on efficacy, durability, safety, convenience, or some combination of these factors? Which competitor should serve as the benchmark?

These questions are difficult to answer without understanding the broader treatment landscape.

By evaluating data across multiple studies, MBMA helps teams establish realistic development targets based on existing clinical performance rather than isolated publications or assumptions. It also helps sponsors understand where a new therapy may offer a competitive advantage and where expectations should be adjusted.

The impact extends well beyond clinical development. The same analyses can help shape target product profiles, commercial strategy, licensing discussions, and portfolio investment decisions years before a pivotal study begins.

3. How do you evaluate a therapy when a randomized control arm is not feasible?

Randomized controlled trials remain the gold standard for generating clinical evidence, but they aren’t always possible. In rare diseases, oncology, and other areas with limited patient populations or rapidly changing standards of care, sponsors often rely on single arm studies to answer important clinical questions.

Even without a control arm, regulators, clinicians, and investors still need to understand how the results compare with existing therapies.

How should the observed treatment effect be interpreted? Would similar patients have achieved the same outcomes with existing therapies? Is the apparent benefit greater than what has historically been observed? These are the situations where carefully constructed external comparators become especially valuable. Using curated clinical trial data, this approach creates quantitative external comparators tailored to the characteristics of a specific study population. Rather than relying on historical averages or narrative literature reviews, the analysis accounts for differences across studies to produce a more meaningful comparison.

“External comparators aren’t intended to replace randomized trials,” Zierhut explains. “They strengthen our ability to interpret single arm studies when traditional trial designs aren’t practical and provide additional evidence to support development and regulatory decisions.”

As innovative trial designs become more common, particularly in rare diseases and precision medicine, these approaches are playing an increasingly important role in helping sponsors generate robust evidence when conventional studies aren’t feasible.

4. How can previous clinical trials improve the next one?

Every clinical trial adds to our understanding of a disease, but too often that knowledge stays within the boundaries of the individual study. Investigators publish their findings, sponsors analyze their own results, and the next trial is designed using a relatively small subset of the available evidence.

Rather than treating every clinical trial as an isolated source of information, MBMA builds on the collective experience of previous studies. By bringing together data from across an indication, it allows development teams to learn from hundreds or even thousands of patients rather than relying on a single publication or internal dataset. That body of evidence can influence decisions made before a protocol is finalized, including dose selection, endpoint strategy, study duration, and patient eligibility criteria.

Just as importantly, it helps teams challenge assumptions. Every development program relies on expectations about treatment effect, placebo response, disease progression, or dose response. When those assumptions are informed by the full body of published evidence instead of a limited number of studies, there’s greater confidence in the decisions that follow.

One recent client collaboration illustrates how this approach works in practice.

In inflammatory diseases, MBMA was used to bridge dose response relationships across related indications, reducing the need for additional dose ranging studies. In hepatitis B, researchers modeled hepatitis B surface antigen loss to estimate the likelihood of achieving a functional cure. In oncology, MBMA linked early tumor response with overall survival, allowing investigators to evaluate alternative trial designs before committing to large, lengthy studies.

Although each project focused on a different scientific question, they all shared the same goal: making better decisions by making better use of existing evidence.

5. Where does our therapy fit within the broader treatment landscape?

Development decisions are rarely made one asset at a time. Portfolio leaders must decide where to invest, which indications offer the greatest opportunity, and which programs are most likely to succeed in an increasingly competitive market.

Looking across multiple studies often reveals trends and relationships that aren’t apparent within a single trial. Certain mechanisms consistently perform better in specific patient populations. Some endpoints prove more sensitive than others. Therapies that appear similar on paper may produce very different outcomes once differences in dose, treatment duration, or patient characteristics are considered.

This perspective becomes even more valuable in crowded disease areas such as obesity, inflammatory diseases, and oncology, where multiple companies are pursuing similar targets at the same time. Understanding how those programs compare helps sponsors make more informed scientific and portfolio decisions long before products reach the market.

Rather than relying solely on published summaries or individual experience, this framework provides a quantitative way to evaluate the totality of evidence and understand where a therapy is most likely to deliver value.

Seeing the bigger picture

Drug development has never had a shortage of data. The challenge has always been turning that data into better decisions. Every year, thousands of clinical studies generate new information, but the real opportunity lies in bringing that evidence together to answer the questions sponsors face every day.

Individual trials will always remain the foundation of drug development, but they rarely tell the whole story. The most important strategic decisions often require understanding how one study fits within the broader body of clinical evidence. Those patterns help explain why one dose succeeds while another fails, why one patient population responds differently than another, and why a strategy that looks promising on paper doesn’t always succeed in practice.

That’s where MBMA has become such an important part of modern drug development. It complements the insights generated from individual trials by placing them within the context of everything that’s already been learned, helping sponsors reduce uncertainty before they make their next decision. For a closer look at where those decisions get hardest, see our companion piece on the clinical development challenges MBMA helps address.

At Certara, those analyses are powered by CODEX, a curated clinical outcomes database covering more than 60 indications, and supported by pharmacometricians, clinicians, statisticians, and therapeutic area specialists. That combination enables sponsors to answer questions that extend well beyond a single study and make decisions grounded in the full body of available evidence.

As development becomes more complex and competition continues to increase, understanding your own trial is no longer enough. The organizations that consistently make better decisions are those that understand how their results fit within the available clinical evidence. That’s exactly what model-based meta-analysis was designed to do.